Palisade Bio Inc. (NASDAQ:PALI) finished Wednesday with a subtraction of -$1.22 to close at $0.72, a downside of -62.70 percent. An average of 962,420 shares of common stock have been traded in the last five days. There was a fall of -$1.3763 in the past week, and it reached a new high 1 time over the past 12 months. The last 20 days have seen an average of 352,410 shares traded, while the 50-day average volume stands at 247,560.
PALI stock has decreased by -59.79% in the last month. The company shares reached their 1-month lowest point of $0.6000 on 08/09/23. With the stock rallying to its 52-week high on 01/03/23, shares of the company touched a low of $1.27 and a high of $27.50 in 52 weeks. It has reached a new high 1 time so far this year and lost -86.08% or -$4.4763 in price. In spite of this, the price is down -97.37% from the 52-week high.
Valuation Metrics
Palisade Bio Inc. (PALI) stock’s beta is 1.66. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 16.43, the price-to-book (PB) ratio at 0.23.
Financial Health
The quick ratio of Palisade Bio Inc. for the three months ended March 30 was 10.90, and the current ratio was 10.90, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending March 30. Its gross profit as reported stood at $15.72 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Palisade Bio Inc.’s return on assets was -90.00%.
Earnings Surprise
The company posted a net income of -$2.34 million in the quarter, while revenues were shrunk -79.91%. The analyst consensus anticipated Palisade Bio Inc.’s latest quarter earnings to come in at -$0.72 per share, but it turned out to be -$0.54, a 25.00% surprise. For the quarter, EBITDA amounted to -$2.53 million. Shareholders own equity worth $6.7 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Palisade Bio Inc. (PALI) price momentum. RSI 9-day as of the close on 09 August was 11.64%, suggesting the stock is oversold, with historical volatility in this time frame at 476.81%.
As of today, PALI’s price is $1.7507 -65.54% or -$1.3763 from its 5-day moving average. PALI is currently trading -66.65% lower than its 20-day SMA and -62.31% lower than its 100-day SMA. However, the stock’s current price level is -46.39% below the SMA50 and -86.43% below the SMA200.
The stochastic %K and %D were 20.14% and 21.73%, respectively, and the average true range (ATR) was 0.2876. With the 14-day stochastic at 6.72% and the average true range at 0.2337, the RSI (14) stands at 19.48%. The stock has reached -0.3981 on the 9-day MACD Oscillator while the 14-day reading was at -0.4893.
Analyst Ratings
The consensus rating for Palisade Bio Inc. (PALI) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell PALI, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 2 others rate it as a “buy”.
What is PALI’s price target for the next 12 months?
Analysts predict a range of price targets between $5.00 and $16.00, with a median target of $10.50. Taking a look at these predictions, the average price target given by analysts for Palisade Bio Inc. (PALI) stock is $10.50.
